Summary of Black Cohosh
Primary Information, Benefits, Effects, and Important Facts
Black Cohosh is a herb native to North America that has traditionally been used for cognitive and inflammatory conditions, but has grown in popularity due to it's ability to treat vasomotor symptoms of menopause; primarily hot flashes and night sweats. It is one of the most popular and highest sold supplements in the Western world (10th place in 2008), according to some surveys.
Studies on the matter are highly mixed. The larger body of evidence favors the efficacy of Black Cohosh for treatment of vasomotor symptoms but consists largely of unblinded studies; as the placebo effect can reduce menopausal complaints, blinding is needed. Efficacy has been demonstrated with blinded studies on Black Cohosh as well, but many of them are confounded with consumption of other compounds. A few blinded studies on Black Cohosh without any other compounds have been conducted, and are basically split right down the middle on efficacy if not favoring 'no significant effects' a little bit more due to quality of data and sample size.
Beyond the questionable efficacy, Black Cohosh appears to be safe. It is non-estrogenic (despite being thought to influence estrogen in the past) and may act centrally (in the brain) via serotonin, dopamine or opioids. Stomach upset has been reported and seems to be attributable to Black Cohosh in some people, but reports of liver toxicity do not appear to be related to the Black Cohosh herb. These reports do exist, but they cannot be linked to Black Cohosh logically.
Things To Know & Note
Also Known As
Cimicifuga racemosa, Bugbane, Bugroot, Snakeroot, Rattleroot, Blackroot, Black Snake Root
Do Not Confuse With
Blue Cohosh (completely different herb)
Goes Well With
St.John's Wort (not synergistic, but both together have shown added efficacy in treating vasomotor symptoms of menopause)
Caution NoticeExamine.com Medical Disclaimer
Black Cohosh has been reported to be associated with liver disease (general hepatotoxicity or auto-immune liver disease), but trials and reviews into the matter have come back inconclusive. Black Cohosh does not appear to be related to these case studies, and tampering of supplements with other herbs in the same genus cannot be ruled out
Might be good to take with a meal, as upset stomachs have been reported at a low rate but consistently in blinded studies
Anecdotes, and some studies, suggest the benefits may be delayed and take a few weeks to kick in
How to Take Black Cohosh
Recommended dosage, active amounts, other details
If using an isopropanolic extract (usually sold under the brand name of Remifemin), 20-40mg daily is used in doses of 20mg; taking 20mg results in a once daily dosing, whereas taking 40mg is twice daily dosing of the 20mg. This dosage (20-40mg) confers 1-2mg of triterpenoid glycosides.
If using an aqueous:ethanolic extract of black cohosh root (ie. not Remifemin) then doses range from 64-128mg daily which are usually taken in two divided doses. This contributed about the same amount of triterpenoid glycosides.
It is not known whether or not black cohosh needs to be taken with food, although it is sometimes recommended to do so out of prudency.
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects black cohosh has on your body, and how strong these effects are.
|Grade||Level of Evidence [show legend]|
|Robust research conducted with repeated double-blind clinical trials|
|Multiple studies where at least two are double-blind and placebo controlled|
|Single double-blind study or multiple cohort studies|
|Uncontrolled or observational studies only|
Level of Evidence
? The amount of high quality evidence. The more evidence, the more we can trust the results.
Magnitude of effect
? The direction and size of the supplement's impact on each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
Consistency of research results
? Scientific research does not always agree. HIGH or VERY HIGH means that most of the scientific research agrees.
|Symptoms of Menopause||Minor||Very High See all 13 studies|
|Anxiety||-||- See study|
|Blood Glucose||-||- See study|
|C-Reactive Protein||-||- See study|
|Cognition||-||- See study|
|Estrogen||-||- See study|
|HDL-C||-||- See study|
|Insulin||-||- See study|
|LDL-C||-||- See study|
|Memory||-||- See study|
|Triglycerides||-||Very High See 2 studies|
|Coronary Heart Disease Risk||Minor||- See study|
|Subjective Well-Being||Minor||- See study|
|Blood Flow||-||- See study|
|Blood Pressure||-||- See study|
|Bone Mineral Density||-||- See study|
|Breast Density||-||- See study|
|Liver Enzymes||-||- See study|
|Weight||-||- See study|
Studies Excluded from Consideration
Scientific Research on Black Cohosh
Click on any below to expand the corresponding section. Click on to collapse it.
Black Cohosh is the colloquial term for the plant Actaea racemosa, also referred to as Cimicifuga racemosa. The supplement contains the dried rhizomes of the plant, and the plant itself is a coarse woodland perennial herb with a thick, knotted root system and growing up to 1-2.5m in height with compound, pinnate leaves up to 7cm in length. The plant is native to North America, spreading from Canada to Georgia. There are a 28 plants in the Actaea genus, of which 8 grow in North America and 5 along the Eastern side (of which Black Cohosh is one of those five). Some versions of the Actaea genus grow in China, and are given the name Shengma; these have traditionally usage for anti-inflammatory conditions, but should not be treated like Black Cohosh.
Black Cohosh has a variety of names such as bugbane or bugwort, blackroot or black snakeroot, or names associated with rattlesnakes (rattle root, rattle weed, rattlesnack root, rattletop). It has been reported to have been used traditionally by certain Native American tribes (Penobscot, Winnebago, Dakota) for the treatment of coughs, colds, constipation, fatigue and rheumatism, as well as to increase breast milk production and tinctures have been reported to have been used for the treatment of pain and inflammation associated with endometriosis, rheumatism, neuralgia and dysmenorrhea as far back as 1832.
As a herbal product, Black Cohosh contains a variety of bioactive compounds such as:
Cycloartanol compounds such as acteol and actein, cimigenol and cimicifugoside; these tend to be seen as the active ingredients and are sometimes referred to simply as triterpene glycosides. There are about 50 of them.
Flavonoids such as Formononectin
Dopargine, a derivative of dopamine
Cimipronidine methyl ester and Cyclo-Cimipronidine
Black Cohosh does not appear to affect P-Glycoprotein and modify the kinetics of drugs subject to P-gp. There is a statistically significant inhibition of CYP2D6 associated with Black Cohosh supplementation over 28 days, but the clinical relevance of it is minor as the enzyme function was inhibited 7.0%. No effect on the CYP2D6 enzyme has been seen over 14 days in another study.
Direct estrogenic action of Black Cohosh, both ethanolic and isopropanolic extracts, is not found when looking in vitro.Effects attributed to estrogen, such as increasing circulating prostacyclin and IL-6 levels from HUVEC cells, are not seen with Black Cohosh supplementation nor is an increase in breast density or uterine weight/thickness, two results attributed to estrogen treatment.
Studies that investigate circulating estradiol concentrations in the blood fail to find significant differences. Due to these results, Black Cohosh is typically seen as non-estrogenic and does not increase circulating estrogen levels.
Studies regarding breast cancer note that Black Cohosh may exert an anti-estrogenic effect, assessed via suppressing proliferation of estrogen-responsive breast cancer cells. Proliferation in these cells was inhibited at a concentration of 1ug/mL, and gene expression overall was suppressed at 100-1000ug/mL.
When looking at isolated compounds in Black Cohosh, the main four triterpenoids compounds (cimiracemoside A, 25-O-methyl-cimigenoside, actein, nor 26-deoxy-actein) fail to increase estrogen levels.
Does not actually possess estrogenic activity nor does it increase circulating estrogen levels. It may be anti-estrogenic as assessed by studies in breast cancer cell lines
Acute supplementation of Black Cohosh in rats has been shown to suppress LH secretion after an injection of 62.5mg Isopropanolic extract (rather unpractical dose, orally).
12 weeks supplementation with 40mg isopropanolic extract Black Cohosh was found to not significantly influence Luteinizing Hormone secretion in post-menopausal women. This parallels a year-long study with Black Cohosh in post menopausal women that, even after double-blind, there were no influences on circulating LH.
Long term human studies suggest no practically relevant suppression of luteinizing hormone associated with Black Cohosh supplementation
Black Cohosh has been found to have no significant influences on FSH in health post-menopausal women.
About seven primary studies have been put forth at this moment in time showing Black Cohosh to be effective in reducing vasomotor symptoms (hot flashes, night sweats) associated with menopause (with a literature extending beyond a dozen studies). A meta-analysis has also been conducted with the inclusion criteria of 40-60 year old healthy peri-menopausal women, excluding studies on breast cancer, studies not in english, and studies without placebo controls (thus, only accepting double blind) and reviewed 9 studies while performing a meta-analysis on 7. Overall, symptoms improved by 26% (Confidence Interval of 11-40%) and this information was derived from a Forest Plot, but the trials were highly hetereogeneous. This conclusion is in accordance with previous literature reviews (but not meta-analysis') on the interactions of Black Cohosh and Vasomotor symptoms.
As mentioned in this study, the above studies that mention benefit associated with Black Cohosh tend to be under 3 months in duration and more often than not measure vasomotor symptoms via self-report rather than using empirical measures. Two studies were not blinded, and the placebo effect has been demonstrated to play a significant role in menopausal symptoms (up to 50% reduction in vasomotor symptoms).
In fact, one 12 month long blinded study comparing black cohosh to placebo found insignificant differences between the two and a double-blinded crossover study with 4 week testing periods failed to find any difference between placebo and Black Cohosh (with a dosage of up to 40mg, an extract similar to Remifemin). These two studies, due to a lack of confounds and lack of industry funding, are arguably of higher quality relative to other studies in Black Cohosh literature.
Of the double blinded studies mentioned in the meta-analysis, three has industry funding. The two studies excluded from meta-analysis due to lack of ability to analyze them both showed positive results. Five studies, although blinded, did not analyze Black Cohosh in isolation and either investigated the combination with St.John's Wort or a multi-botanical approach.
Overall, there appears to be a slight trend towards beneficial effects on hot flashes and night sweats associated with Black Cohosh. There is a large amount of studies showing this benefit, but many are unblinded (on a topic where the placebo effect can confer tons of benefit) and the double blind studies are many times confounded with other supplements (making it hard to attribute the benefit to Black Cohosh).
In a rat model of menopause, it has been demonstrated that although Black Cohosh was effective in reducing the abnormalities in thermoregulation associated with ovariectomization it's efficacy was delayed, taking longer to come into effect.
In post-menopausal rats, spiking the food with Black Cohosh is able to reduce a 53.7% bone loss over time to 38.7%. Beneficial trends are seen in humans as well in regards to bone metabolism when measuring urinary markers or when measuring alkaline phosphatase, but the only human trial to measure Bone Mineral Density found no effects of Black Cohosh Intervention.
Black Cohosh has been demonstrated to reduce menopausal symptoms during concomitant treatment with Tamoxifen with good tolerability.
Some rat studies note a passive decrease in food intake in foods spiked with Black Cohosh.
Acutely, Black Cohosh appears to activate human mu-opioid receptors with an EC50 of 68.8+/-7.7 microg/mL, and can displace other ligands on the receptor.
Over a period of 12 weeks, Black Cohosh appears to increase binding activity for mu-opiod receptors in a variety of brain regions after ingestion of 40mg isopropanolic extract daily (Remifemin), ranging from 10% in the Nuclear Accumbens to a 61% increase in the posterior cingulate. This can potentially increase the effects of opioids in vivo.
Serotonin was investigated for Black Cohosh as the system is related to thermoregulation, and it was found that a component of Black Cohosh known as N(omega)-Methylserotonin was able to activate a serotonin receptor (5-HT7) and act as an SSRI, with a receptor binding IC50 of 23pM and SSRI IC50 of 490nM. The triterpenoid structures were found to not be active agonists of this receptor.
Remifemin is a proprietary blend of Black Cohosh. Served in tablets, each tablet contains 0.018–0.026mL liquid extract of black cohosh rootstock that varies in concentration from 6-11:1. This correlates to about 20mg active drug per capsule, or 2.5mg dry weight Black Cohosh (with a 40% vol/vol isopropanol extraction) per capsule. Remifemin aims to deliver 1mg triterpenoid glycosides per capsule.
BNO 1055 is a patented extract of Black Cohosh used in some research studies. It is an aqueous/ethanolic extract of the plant's rhizomes. The extraction is a process with five times the amount of 50% m/m/water/ethanol for 48 h with a percolation speed of 500 kg/h. After filtration the extract was concentrated in vacuum and evaporated to dryness at 100–140 mbar according to a patent protected process.
St.John's Wort is a herbal anti-depressant with the active compound of Hypericin and the botanical name of Hypericum perforatum; it is usually paired with Black Cohosh as St.John's Wort is also shown to decrease menopausal symptoms in pilot studies.
An isopropanolic extract of Black Cohosh paired with St.John's Wort has shown efficacy in reducing symptoms of menopause and also depression simultenaously in a double blind study and in reducing symptoms of hot flashes while simultaneously increasing HDL relative to control (but not baseline); this latter study was funded by the makers of the tested nutrient formulation, however.
The only study to compare Black Cohosh against the combination was an unblinded but controlled study, and found the combination to be superior but not synergistically so.
Both compounds seem to be complementary towards the same goals, but have not yet been shown to 'work together' or be synergistic
When looking at vaginal bleeding in postmenopausal women, one large scaled (yet unblinded) study noted no instances of vaginal bleeding in 90 women assigned to take 40mg of Remifemin daily.
A study on 400 women measuring endometrial thickness via biopsy after 52 weeks of supplementation with the BNO 1055 extract of Black Cohosh failed to show any increases in endometrial thickness or vaginal hyperplasia despite being able to reduce hot flashes.
No significant adverse effects related to menopause or estrogen have been reported with Black Cohosh supplementation, although an increase of breast tenderness and swelling has been noted in some studies
According to one review, at least 50 isolated cases associated with Black Cohosh supplementation have been reported, although none of these cases could causation be drawn to blame Black Cohosh. These case reports sprung up around 2002 and the few years following.
A meta-analysis of past studies noted that clinical trials had over 2,000 participants leading up to 2010, with no cases of reported hepatotoxcity. This meta-analysis in particular analyzed data from 1,020 women and found no evidence of hepatotoxicity associated with Black Cohosh in the range of 40-128mg herbal extract using an isopropanolic mixture (Remifemin, usually). At least two scientific workshops from The National Centre for Complementary and Alternative Medicine National Institutes of Health in collaboration with The National Institutes of Health Office of Dietary Supplements found a significant discord between what the literature says and case reports.
When investigating this claim via trials, a trial of 87 otherwise healthy postmenopausal women (without pre-existing liver abnormalities) did not find any significant influences on the liver associated with Black Cohosh supplementation; no alterations in bilirubin, hepatic blood flow, or lipoproteins were recorded after 12 months of Black Cohosh usage.
Due to the popularity of Black Cohosh, ranking as the 10th most popular nutraceutical in the year of 2008, it is possible that said hepatotoxicity is due to poor regulation and spiking of 'Black Cohosh' products. A study investigating popular sold Cohosh products found that some did not contain Black Cohosh, but asian varieties of the Actaea genus that have not been as adequately studied.
There are indeed case studies associating Black Cohosh supplementation with liver failure, but whether this is actually due to the Black Cohosh plant is not known. Attempts to prove toxic effects to the liver have failed and controlled trials have not noted any dysfunction to the liver's functions; the possibility of tainted supplements due to the popularity of Black Cohosh cannot be ruled out
One study noted a patient withdrawal from 32mg Black Cohosh associated with edema and athralgia and a large open study noted that 16% of women using 40mg of Remifemin daily experienced breast swelling. A pharmacodynamic study on enzyme interactions had one subject report 'vivid dreams'.
A large scale controlled trial on black cohosh (and a combination therapy of black cohosh and St.John's Wort) found that the possible treatment-related side effects in a sample of 6141 women was 0.16%, and all non-serious. A meta-analysis of 9 double blind trials noted that gastrointestinal upset was the only concern which could be attributed to Black Cohosh, at percentages ranging from 0.5% to 15% of subjects; systemic reviews also note lack of reliable and significant demonstrated harm associated with Black Cohosh.
- Sammartino A, et al. Short-term effects of a combination of isoflavones, lignans and Cimicifuga racemosa on climacteric-related symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled trial. Gynecol Endocrinol. (2006)
- Verhoeven MO, et al. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause. (2005)
- Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol. (2007)
- WHO Monograph: Rhizoma Cimicifugae Racemosae.
- Jiang B, et al. Phytochemical fingerprinting to thwart black cohosh adulteration: a 15 Actaea species analysis. Phytochem Anal. (2011)
- Mahady GB, et al. Black cohosh (Actaea racemosa) for the mitigation of menopausal symptoms: recent developments in clinical safety and efficacy. Womens Health (Lond Engl). (2006)
- Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol. (2005)
- Chen SN, et al. Isolation, structure elucidation, and absolute configuration of 26-deoxyactein from Cimicifuga racemosa and clarification of nomenclature associated with 27-deoxyactein. J Nat Prod. (2002)
- Bedir E, Khan IA. Cimiracemoside a: A new cyclolanostanol xyloside from the rhizome of Cimicifuga racemosa. Chem Pharm Bull (Tokyo). (2000)
- Bedir E, Khan IA. A new cyclolanostanol arabinoside from the rhizome of Cimicifuga racemosa. Pharmazie. (2001)
- Shao Y, et al. Triterpene glycosides from Cimicifuga racemosa. J Nat Prod. (2000)
- Watanabe K, et al. Cycloartane glycosides from the rhizomes of Cimicifuga racemosa and their cytotoxic activities. Chem Pharm Bull (Tokyo). (2002)
- Triterpene Glycosides from Cimicifuga racemosa.
- Gödecke T, et al. Guanidine alkaloids and Pictet-Spengler adducts from black cohosh (Cimicifuga racemosa). J Nat Prod. (2009)
- Powell SL, et al. In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent. J Agric Food Chem. (2008)
- Gurley BJ, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. (2006)
- Gurley BJ, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. (2005)
- Gurley BJ, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res. (2008)
- Zierau O, et al. Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol. (2002)
- Pineda B, et al. No effect of Cimicifuga racemosa extract on serum interleukin-6 levels and prostacyclin production by human endothelial cells. Eur J Obstet Gynecol Reprod Biol. (2009)
- Lundström E, Hirschberg AL, Söderqvist G. Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. Maturitas. (2011)
- Seidlova-Wuttke D, et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol. (2003)
- Liske E, et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med. (2002)
- Reame NE, et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause. (2008)
- Reed SD, et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause. (2008)
- Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat. (2002)
- Bodinet C, Freudenstein J. Influence of marketed herbal menopause preparations on MCF-7 cell proliferation. Menopause. (2004)
- Zhang L, et al. In vivo effects of black cohosh and genistein on estrogenic activity and lipid peroxidation in Japanese Medaka (Oryzias latipes). J Herb Pharmacother. (2003)
- Seidlová-Wuttke D, Thelen P, Wuttke W. Inhibitory effects of a black cohosh (Cimicifuga racemosa) extract on prostate cancer. Planta Med. (2006)
- Frei-Kleiner S, et al. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas. (2005)
- Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. Zentralbl Gynakol. (1988)
- Nappi RE, et al. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. (2005)
- Bai W, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas. (2007)
- Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas. (2003)
- Osmers R, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. (2005)
- Shams T, et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med. (2010)
- Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol. (2002)
- Philp HA. Hot flashes--a review of the literature on alternative and complementary treatment approaches. Altern Med Rev. (2003)
- Geller SE, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause. (2009)
- MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev. (2001)
- Newton KM, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. (2006)
- Pockaj BA, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. (2006)
- Uebelhack R, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol. (2006)
- Chung DJ, et al. Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J. (2007)
- Ma X, et al. Effects of an isopropanolic-aqueous black cohosh extract on central body temperature of ovariectomized rats. J Ethnopharmacol. (2011)
- Wuttke W, Gorkow C, Seidlová-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause. (2006)
- García-Pérez MA, et al. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertil Steril. (2009)
- Bebenek M, et al. Effect of exercise and Cimicifuga racemosa (CR BNO 1055) on bone mineral density, 10-year coronary heart disease risk, and menopausal complaints: the randomized controlled Training and Cimicifuga racemosa Erlangen (TRACE) study. Menopause. (2010)
- Rostock M, et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study. Gynecol Endocrinol. (2011)
- Kapur P, Wuttke W, Seidlova-Wuttke D. The Cimicifuga racemosa special extract BNO 1055 prevents hot flashes in ovariectomized rats. Phytomedicine. (2010)
- Rhyu MR, et al. Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. J Agric Food Chem. (2006)
- Hirschberg AL, et al. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause. (2007)
- Process for the mild reduction of germs in pharmaceutical preparations.
- Al-Akoum M, et al. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause. (2009)
- Briese V, et al. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment--results of a large-scale, controlled, observational study. Maturitas. (2007)
- Bai WP, et al. Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms. Zhonghua Fu Chan Ke Za Zhi. (2009)
- Raus K, et al. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause. (2006)
- Black Cohosh Hepatic Safety: Follow-Up of 107 Patients Consuming a Special Cimicifuga racemosa rhizome Herbal Extract and Review of Literature.
- Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust. (2002)
- Lontos S, et al. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust. (2003)
- Cohen SM, et al. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause. (2004)
- Naser B, et al. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause. (2011)
- Nasr A, Nafeh H. Influence of black cohosh (Cimicifuga racemosa) use by postmenopausal women on total hepatic perfusion and liver functions. Fertil Steril. (2009)
- Jiang B, et al. Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by high-performance liquid chromatography with selected ion monitoring liquid chromatography-mass spectrometry. J Agric Food Chem. (2006)
- Amsterdam JD, et al. Randomized, double-blind, placebo-controlled trial of Cimicifuga racemosa (black cohosh) in women with anxiety disorder due to menopause. J Clin Psychopharmacol. (2009)
- Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. Am J Obstet Gynecol. (2008)
- Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause. (2010)
- Spangler L, et al. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. Maturitas. (2007)
- Ross SM. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract. (2012)
- Jacobson JS, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. (2001)
- Maki PM, et al. Effects of botanicals and combined hormone therapy on cognition in postmenopausal women. Menopause. (2009)
- Juliá Mollá MD, et al. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. Gynecol Endocrinol. (2009)
- Verhoeven MO, et al. Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women. Fertil Steril. (2007)